Alfredo Berruti spends much of his time researching Internal medicine, Oncology, Surgery, Adrenocortical carcinoma and Endocrinology. Many of his studies on Internal medicine apply to Gastroenterology as well. His studies deal with areas such as Epirubicin, Cyclophosphamide, Immunology, Systemic therapy and Vitamin D and neurology as well as Oncology.
His Adrenocortical carcinoma study incorporates themes from Adrenal Cortex Carcinoma, Phases of clinical research, Retrospective cohort study, Stage and Adjuvant therapy. His study in Endocrinology is interdisciplinary in nature, drawing from both Androgen deprivation therapy and Prostate cancer. His Chemotherapy research includes themes of Regimen and Pharmacology.
Alfredo Berruti focuses on Internal medicine, Oncology, Chemotherapy, Prostate cancer and Breast cancer. His Internal medicine research incorporates themes from Gastroenterology, Endocrinology and Surgery. His Oncology research includes elements of Cyclophosphamide, Disease, Retrospective cohort study and Hazard ratio.
His research on Chemotherapy often connects related topics like Regimen. Alfredo Berruti combines subjects such as Prostate, Chromogranin A and Urology with his study of Prostate cancer. Alfredo Berruti studies Mitotane which is a part of Adrenocortical carcinoma.
Internal medicine, Oncology, Adrenocortical carcinoma, Prostate cancer and Mitotane are his primary areas of study. In his study, Immunohistochemistry is strongly linked to Endocrinology, which falls under the umbrella field of Internal medicine. His research integrates issues of Nivolumab, Adverse effect, Proportional hazards model and Hazard ratio in his study of Oncology.
His Adrenocortical carcinoma study combines topics from a wide range of disciplines, such as Cancer research, Randomized controlled trial, Surgery, Molecular biology and Rare disease. His work deals with themes such as Bone health and Docetaxel, which intersect with Prostate cancer. As a part of the same scientific family, Alfredo Berruti mostly works in the field of Mitotane, focusing on Adjuvant and, on occasion, Radical surgery.
Alfredo Berruti mostly deals with Internal medicine, Oncology, Clinical Practice, Chemotherapy and Hazard ratio. His research in Internal medicine intersects with topics in Endocrinology and Perioperative. His work on Mitotane as part of general Endocrinology research is often related to Context, thus linking different fields of science.
His Oncology research is multidisciplinary, incorporating elements of Cancer, Breast cancer, Prostate cancer, Meta-analysis and Recurrent glioblastoma. His work carried out in the field of Chemotherapy brings together such families of science as Lesion, Neuroradiology, Group B, Colorectal cancer and Survival analysis. His Hazard ratio study integrates concerns from other disciplines, such as Proportional hazards model and Retrospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adjuvant mitotane treatment for adrenocortical carcinoma.
Massimo Terzolo;Alberto Angeli;Martin Fassnacht;Fulvia Daffara.
The New England Journal of Medicine (2007)
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
S. Bovio;A. Cataldi;G. Reimondo;P. Sperone.
Journal of Endocrinological Investigation (2006)
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht;Massimo Terzolo;Bruno Allolio;Eric Baudin.
The New England Journal of Medicine (2012)
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Martin Fassnacht;Olaf M. Dekkers;Olaf M. Dekkers;Tobias Else;Eric Baudin;Eric Baudin.
European Journal of Endocrinology (2018)
Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy
Alfredo Berruti;Luigi Dogliotti;Carlo Terrone;Stefania Cerutti.
The Journal of Urology (2002)
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Berruti;E. Baudin;H. Gelderblom;H. R. Haak.
Annals of Oncology (2012)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
S Filetti;C Durante;D Hartl;D Hartl;S Leboulleux;S Leboulleux.
Annals of Oncology (2019)
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Alfredo Berruti;Massimo Terzolo;Paola Sperone;Anna Pia.
Endocrine-related Cancer (2005)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Marianne Pavel;Kjell Öberg;Massimo Falconi;Eric Krenning.
Annals of Oncology (2020)
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Daniele Generali;Alfredo Berruti;Maria P Brizzi;Leticia Campo.
Clinical Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: